TG Therapeutics licenses antibodies from newly formed Checkpoint Therapeutics
Checkpoint Therapeutics Inc., a newly formed division of Coronado Biosciences Inc., granted TG Therapeutics Inc. exclusive rights to develop and sell two immuno-oncology antibodies.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.